Evidence map›Paper›PMID 38360615›Full record

ArticleJournal of nanobiotechnology2024

Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085.

Bingqing Hui, Chenchen Zhou, Yetao Xu, Rui Wang, Yuwen Dong, Yirui Zhou, Jie Ding, Xiao Zhang, Jian Xu, Yanhong Gu

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 34 citations in OpenAlex.

  1. Microorganisms · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. MedComm · 2025
    Review
  9. Cancers · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Impact ofFrontiers in immunology · 2025
    Article
  17. Review
  18. Review
  19. Review
  20. Potential and application ofFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bingqing Hui *Department of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Chenchen Zhou *Department of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yetao Xu *The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu, China.
Rui WangDepartment of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yuwen DongDepartment of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Yirui ZhouDepartment of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Jie DingDepartment of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Xiao ZhangDepartment of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. 13820936563@163.com.
Jian XuDepartment of General Surgery, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. mexujian@126.com.
Yanhong GuDepartment of Oncology and Cancer Rehabilitation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. guyhphd@163.com.
Nanjing Medical University · CNJiangsu Province Hospital · CNSecond Affiliated Hospital of Nanjing Medical University · CN

Funding

Jiangsu Funding Program for Excellent Postdoctoral Talent 2023ZB777National Natural Science Foundation of China 81802373National Natural Science Foundation of China 82273197National Natural Science Foundation of China 82371696Postdoctoral Research Foundation of the First Affiliated Hospital of Nanjing Medical University BSH202112
6 · The paper itself

Abstract

backgroundA large number of Fusobacterium nucleatum (Fn) are present in colorectal cancer (CRC) tissues of patients who relapse after chemotherapy, and Fn has been reported to promote oxaliplatin and 5-FU chemoresistance in CRC. Pathogens such as bacteria and parasites stimulate exosome production in tumor cells, and the regulatory mechanism of exosomal circRNA in the transmission of oxaliplatin and 5-FU chemotherapy resistance in Fn-infected CRC remains unclear.

methodsHsa_circ_0004085 was screened by second-generation sequencing of CRC tissues. The correlation between hsa_circ_0004085 and patient clinical response to oxaliplatin/5-FU was analyzed. Exosome tracing experiments and live imaging systems were used to test the effect of Fn infection in CRC on the distribution of hsa_circ_0004085. Colony formation, ER tracking analysis and immunofluorescence were carried out to verify the regulatory effect of exosomes produced by Fn-infected CRC cells on chemotherapeutic resistance and ER stress. RNA pulldown, LC-MS/MS analysis and RIP were used to explore the regulatory mechanism of downstream target genes by hsa_circ_0004085.

resultsFirst, we screened out hsa_circ_0004085 with abnormally high expression in CRC clinical samples infected with Fn and found that patients with high expression of hsa_circ_0004085 in plasma had a poor clinical response to oxaliplatin/5-FU. Subsequently, the circular structure of hsa_circ_0004085 was identified. Fn infection promoted hsa_circ_0004085 formation by hnRNP L and packaged hsa_circ_0004085 into exosomes by hnRNP A1. Exosomes produced by Fn-infected CRC cells transferred hsa_circ_0004085 between cells and delivered oxaliplatin/5-FU resistance to recipient cells by relieving ER stress. Hsa_circ_0004085 enhanced the stability of GRP78 mRNA by binding to RRBP1 and promoted the nuclear translocation of ATF6p50 to relieve ER stress.

conclusionsPlasma levels of hsa_circ_0004085 are increased in colon cancer patients with intracellular Fn and are associated with a poor response to oxaliplatin/5-FU. Fn infection promoted hsa_circ_0004085 formation by hnRNP L and packaged hsa_circ_0004085 into exosomes by hnRNP A1. Exosomes secreted by Fn-infected CRC cells deliver hsa_circ_0004085 between cells. Hsa_circ_0004085 relieves ER stress in recipient cells by regulating GRP78 and ATF6p50, thereby delivering resistance to oxaliplatin and 5-FU.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsExosomesHeterogeneous-Nuclear Ribonucleoprotein LMicroRNAsCell ProliferationChromatography, LiquidEndoplasmic Reticulum Chaperone BiPFluorouracilFusobacterium nucleatumHeterogeneous Nuclear Ribonucleoprotein A1HumansOxaliplatinTandem Mass SpectrometryEndoplasmic Reticulum Chaperone BiPFluorouracilHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein LMicroRNAsOxaliplatinChemoresistance of colon cancerEndoplasmic reticulum stressExosomesFusobacterium nucleatumhsa_circ_0004085

Identifiers

PMID38360615
PMCPMC10867993
OpenAlexW4391841061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.